


FIG. 1a




FIG. 1b




FIG. 2




FIG. 3a




FIG. 3b




FIG. 3c



SW480 Tumor Volume
Tumor Volume
(mean mm3 ± SEM)
4000
3000
2000
1000
0
0
5
10
15
20
25
30
Treatment days
Vehicle (Saline)
Anti-VEGF antibody , 5mg/kg
IgG1-ADC (DAR8), 10mg/kg
VEGF-ADC-01 (DAR8), 5mg/kg
VEGF-ADC-01(DAR8), 10mg/kg
VEGF-ADC-01(DAR4), 10mg/kg
VEGF-ADC-01(DAR4), 20mg/kg
Administration

FIG. 4



SW480 Body Weight
Body Weight
(mean g ± SEM)
30
28
26
24
22
20
18
0
5
10
15
20
25
30
Treatment days
Vehicle (Saline)
Anti-VEGF antibody , 5mg/kg
IgG1-ADC (DAR8), 10mg/kg
VEGF-ADC-01 (DAR8), 5mg/kg
VEGF-ADC-01 (DAR8), 10mg/kg
VEGF-ADC-01 (DAR4), 10mg/kg
VEGF-ADC-01 (DAR4), 20mg/kg
Administration

FIG. 5



NCI-H358 CDX model - lung cancer
Tumor volume
(mean mm3 ±SEM)
1200
900
600
300
0
0
5
10
15
20
25
Days post grouping
Normal saline
Anti-VEGF antibody, 3mg/kg
Toxin, 0.07mg/kg
IgG1-ADC(DAR4), 3mg/kg
VEGF-ADC-01(DAR4), 0.5mg/kg
VEGF-ADC-01(DAR4), 1mg/kg
VEGF-ADC-01(DAR4), 3mg/kg
Administration

FIG. 6



NCI-H358 model - body weight of mice
Body weight (g)
28
26
24
22
20
18
0
5
10
15
20
25
Days post grouping
Normal saline
Anti-VEGF antibody, 3mg/kg
Toxin, 0.07mg/kg
IgG1-ADC(DAR4), 3mg/kg
VEGF-ADC-01(DAR4), 0.5mg/kg
VEGF-ADC-01(DAR4), 1mg/kg
VEGF-ADC-01(DAR4), 3mg/kg
Administration

FIG. 7



Tumor Volume
Tumor Volume (mean mm3 ±SEM)
1500
1000
500
0
0
5
10
15
20
25
Treatment days
Vehicle
Anti-VEGF antibody, 5mg/kg
IgG1-ADC(DAR4), 5mg//kg
VEGF-ADC-01(DAR4), 5mg/kg
Administration

FIG. 8



Body Weight (g)
30
25
20
15
0
5
10
15
20
25
Days after treatment
Vehicle
Anti-VEGF antibody, 5mg/kg
IgG1-ADC(DAR4), 5mg/kg
VEGF-ADC-01(DAR4), 5 mg/kg
Administration

FIG. 9